Typicality: | 0.380 |
Saliency: | 0.304 |
for treating patients | 5 | purpose |
in 2001 | 5 | temporal |
in both children | 2 | other |
use → be approved by → the fda | 25 |
use → approved by → fda | 8 |
use → be approved by → fda | 6 |
negative | neutral | positive |
0.207 | 0.603 | 0.190 |
Raw frequency | 39 |
Normalized frequency | 0.304 |
Modifier score | 0.500 |
Perplexity | 24.927 |